Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#25 of 3,479)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 50 news outlets

twitter: 8 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 7 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 106 news stories from 50 outlets.

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

USA Life Sciences Database, 22 Mar 2024

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Morning Star, 22 Mar 2024

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc.

News story from Finanz Nachrichten on Friday 22 March 2024

Finanz Nachrichten, 22 Mar 2024

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Stockwatch, 22 Mar 2024

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 102 additional news stories.